Novavax gains on RSV vaccine results

Novavax Inc. (NASDAQ:NVAX) gained $1.16 (10%) to $12.35 in after-hours trading after reporting top-line Phase II data for its RSV F vaccine to prevent respiratory syncytial virus (RSV) infection in elderly, community-living patients. Novavax said it was the first study to show efficacy in RSV immunization.

In the 1,600-patient trial, a per-protocol analysis showed an unadjuvanted 135 ug dose of RSV F vaccine reduced the incidence of all symptomatic RSV disease vs. placebo by 44%, meeting a prespecified exploratory efficacy outcome. The treatment group had 21 cases, while the placebo group had 38; the difference was statistically significant. ...